AJP - Heart BIOPAC complete lab solutions
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 288: H1037-H1043, 2005. First published September 16, 2004; doi:10.1152/ajpheart.00677.2004
0363-6135/05 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/3/H1037    most recent
00677.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (31)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schiffrin, E. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schiffrin, E. L.

8TH INTERNATIONAL SYMPOSIUM ON RESISTANCE ARTERIES
New Developments in Resistance Artery Research: From Molecular Biology to Bedside

Peroxisome proliferator-activated receptors and cardiovascular remodeling

Ernesto L. Schiffrin

Canadian Institute of Health Research Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, Montreal, Quebec, Canada

Submitted 27 July 2004 ; accepted in final form 28 September 2004


   ABSTRACT
TOP
 ABSTRACT
VASCULAR EFFECTS OF PPAR-{alpha}
 VASCULAR EFFECTS OF PPAR-{gamma}
 CARDIAC EFFECTS OF PPARs
 CONCLUSION
 GRANTS
 REFERENCES
 
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that heterodimerize with the retinoid X receptor and then modulate the function of many target genes. Three PPARs are known: {alpha}, {beta}/{delta}, and {gamma}. The better known are PPAR-{alpha} and PPAR-{gamma}, which may be activated by different synthetic agonists, although the endogenous ligands are unknown. PPAR-{alpha} is involved in fatty acid oxidation and expressed in the liver, kidney, and skeletal muscle, whereas PPAR-{gamma} is involved in fat cell differentiation, lipid storage, and insulin sensitivity. However, both have been shown to be present in variable amounts in cardiovascular tissues, including endothelium, smooth muscle cells, macrophages, and the heart. The activators of PPAR-{alpha} (fibrates) and PPAR-{gamma} (thiazolidinediones or glitazones) antagonized the actions of angiotensin II in vivo and in vitro and exerted cardiovascular antioxidant and anti-inflammatory effects. PPAR activators lowered blood pressure, induced favorable effects on the heart, and corrected vascular structure and endothelial dysfunction in several rodent models of hypertension. Activators of PPARs may become therapeutic agents useful in the prevention of cardiovascular disease beyond their effects on carbohydrate and lipid metabolism. Some side effects, such as weight gain, as well as documented aggravation of advanced heart failure through fluid retention by glitazones, may, however, limit their therapeutic application in prevention of cardiovascular disease.

arteries; endothelium; heart; inflammation

PEROXISOME PROLIFERATOR-ACTIVATED receptors (PPARs) are nuclear factors initially shown to respond to xenobiotics with peroxisomal proliferation in the rodent liver (30). Later, they were demonstrated to modulate genes that regulate lipid and glucose metabolism (for review see Ref. 40). More recently, PPARs have been shown to participate in the regulation of cell growth and migration (36), oxidant stress (16, 59), and inflammation (13) in the cardiovascular system. PPAR-{alpha} is found in tissues where fatty acid catabolism is important (liver, kidney, heart, and muscle) and is stimulated by natural ligands such as fatty acids and eicosanoids (e.g., leukotriene B4) and by synthetic ligands, the lipid-lowering fibrates (14). PPAR-{alpha} affects target genes that participate in {omega}- and {beta}-oxidation of fatty acids. PPAR-{beta}/{delta} is expressed in many tissues (6, 34). Recent evidence suggests that PPAR-{beta}/{delta} is involved in fatty acid and lipid metabolism, particularly in skeletal muscle (9, 40, 60). This may also occur in cardiovascular tissues (23). PPAR-{gamma} controls adipocyte differentiation and lipid storage (60) and is accordingly highly expressed in adipose tissue. Through its effects on adipose tissue and skeletal muscle, PPAR-{gamma} regulates the action of insulin. Selective activators of PPAR-{gamma} are the insulin sensitizers thiazolidinediones or glitazones, such as troglitazone, pioglitazone, and rosiglitazone.

PPARs have an NH2-terminal domain that regulates PPAR activity, a DNA binding domain that binds to the PPAR response element (PPRE) in the promoter region of target genes, a domain for a cofactor, and a COOH-terminal ligand-binding domain that determines ligand specificity (62). PPARs are bound to corepressor proteins when inactive. After stimulation by PPAR activators, PPARs dissociate from corepressors and recruit coactivators, which include a PPAR-binding protein and the steroid receptor coactivator-1 (37), and heterodimerize with retinoid X receptor-{alpha}. They then bind to PPRE in target genes to modulate gene transcription (27). Gene regulation by this mechanism results in the action of PPARs on carbohydrate and lipid metabolism (Fig. 1) . PPAR-{alpha} and PPAR-{gamma} also exert numerous effects by interaction with different transcription factors to repress proinflammatory genes (Fig. 1). Although the effects on carbohydrate and lipid metabolism affect the cardiovascular system mainly through their impact on atherogenesis, the anti-inflammatory and antioxidant actions of PPARs affect cardiovascular remodeling in many ways. Effects of PPARs on cardiovascular remodeling are the main subject of the present review, beyond their regulatory effects on glucose and lipid metabolism, which have been reviewed recently (40).



View larger version (25K):
[in this window]
[in a new window]
  		Fig. 1. Mechanism of action of peroxisome proliferator-activated receptors (PPARs). After activation by ligand binding, PPARs heterodimerize with retinoid X receptor (RXR) and bind to specific PPAR response elements (PPRE) on the promoter of target genes to regulate glucose and lipid metabolism (right). This aspect of PPAR-{alpha} and PPAR-{gamma} action, which has cardiovascular protective effects through effects on atherosclerosis and diabetes, is not discussed in the present review. Left: interaction of PPAR-{alpha} and PPAR-{gamma} with different transcription factors to repress proinflammatory genes. VCAM, vascular cell adhesion molecule; ICAM, intercellular adhesion molecule; PECAM, platelet and endothelial cell adhesion molecule; AP, activator protein; CCAAT/EBP, CCAAT/enhancer binding protein; CRP, C-reactive protein; MCP, monocyte chemoattractant protein; CD40L, CD40 ligand; MMP, matrix metalloproteinase; iNOS, inducible nitric oxide synthase; VSMCs, vascular smooth muscle cells; FA, fatty acid.

 

   VASCULAR EFFECTS OF PPAR-{alpha}
TOP
 ABSTRACT
 VASCULAR EFFECTS OF PPAR-{alpha}
VASCULAR EFFECTS OF PPAR-{gamma}
 CARDIAC EFFECTS OF PPARs
 CONCLUSION
 GRANTS
 REFERENCES
 
PPAR-{alpha} and PPAR-{gamma} are expressed in the cardiovascular system (5). PPAR-{alpha} is found in endothelial cells (28), vascular smooth muscle cells (VSMCs) (56), and monocytes/macrophages (10). The role of these nuclear factors in the vasculature and the heart has been revealed over the past few years (40). The PPAR-{alpha} ligand docosahexaenoic acid (DHA) was shown to have proapoptotic effects on cultured VSMCs (19) that were mediated by activation of p38 mitogen-activated protein kinase (21). Anti-inflammatory effects were demonstrated by the inhibition by PPAR-{alpha} ligands of interleukin (IL)-1{beta}-induced production of IL-6 and prostaglandins and expression of cyclooxygenase-2. These effects occurred as a consequence of PPAR-{alpha} inhibition of signaling by the proinflammatory mediator nuclear factor-{kappa}B (NF-{kappa}B) and induction of apoptosis (10). Antagonism of signaling by NF-{kappa}B was also demonstrated by other investigators (12, 46). PPAR-{alpha} activators also downregulated cytokine-induced genes, such as vascular cell adhesion molecule (VCAM)-1 and tissue factor, in endothelial cells (42). PPAR-{alpha}-deficient mice demonstrated enhanced inflammatory responses to lipopolysaccharide (LPS) administration, and, in these mice, fibrates were unable to affect LPS-induced IL-6 (12). The PPAR-{alpha} activator fenofibrate also reduced plasma concentrations of the cytokines interferon-{gamma} and tumor necrosis factor-{alpha} (TNF-{alpha}) in patients with hyperlipoproteinemia IIb (38).

Because PPARs might antagonize the effects of angiotensin II (ANG II), the action of the PPAR-{alpha} activator DHA was investigated in ANG II-infused rats (16). DHA reduced ANG II-induced oxidative stress (as demonstrated by NADPH oxidase activity measured by chemiluminescence) and expression of inflammatory mediators [the adhesion molecules intercellular adhesion molecule (ICAM-1) and VCAM-1] in blood vessels of ANG II-infused rats. Blood pressure (BP), elevated by ANG II, was reduced by DHA. The remodeling of small resistance arteries induced by ANG II was abrogated by the PPAR-{alpha} activator. Concomitantly, endothelial dysfunction typically found under ANG II infusion was prevented by DHA, together with reduction in NADPH oxidase-dependent superoxide anion formation. Although these effects cannot be conclusively and unambiguously shown to be unrelated to BP reduction, in some models such as the deoxycorticosterone acetate (DOCA)-salt hypertensive rat, they have occurred in response to PPAR-{alpha} activators in the absence of significant decline in BP (26). This suggests that they are probably not dependent on reduction of BP.

Recent studies have elucidated some of the mechanisms involved in the beneficial effects of PPAR-{alpha} activation on endothelial function. Goya et al. (24) demonstrated that fenofibrate increases endothelial nitric oxide (NO) synthase (eNOS) expression in bovine aortic endothelial cells. Interestingly, this does not occur through effects on eNOS gene promoter activity but, rather, through increases in mRNA stability (24).


   VASCULAR EFFECTS OF PPAR-{gamma}
TOP
 ABSTRACT
 VASCULAR EFFECTS OF PPAR-{alpha}
 VASCULAR EFFECTS OF PPAR-{gamma}
CARDIAC EFFECTS OF PPARs
 CONCLUSION
 GRANTS
 REFERENCES
 
Similar to PPAR-{alpha}, PPAR-{gamma} has been reported to be present in the vasculature (40) and was demonstrated in endothelial cells (52), VSMCs (20, 35), and monocytes/macrophages (50). PPAR-{gamma} activators inhibited proliferation and migration of VSMCs (35, 36). They enhanced expression of PPAR-{gamma} in macrophages and inhibited expression of inducible NO synthase (iNOS), matrix metalloproteinase (MMP)-9, and scavenger receptor A. These effects of PPAR-{gamma} were mediated in part by inhibition of transcription factors activator protein-1 (AP-1), signal transducer and activator of transcription, and NF-{kappa}B. PPAR-{gamma} activators inhibited expression of TNF-{alpha}, IL-6, IL-1{beta} (31), iNOS, MMP-9, and scavenger receptor A in monocytes (49). PPAR-{gamma} activators attenuated TNF-induced VCAM-1 and ICAM-1 expression in endothelial cells and reduced monocyte/macrophage homing to atherosclerotic plaques in apolipoprotein E-deficient mice (45). PPAR-{gamma} expression has indeed been demonstrated in human atherosclerotic plaques (48). However, 15-deoxy-{Delta}12,14-prostaglandin (15d-PG) J2 may stimulate the synthesis of IL-8 in endothelial cells in a PPAR-{gamma}-independent manner (32). Mechanisms whereby PPAR-{gamma} activation may induce anti-inflammatory effects include interactions with CCAAT/enhancer-binding protein-{delta}, present in tandem repeats in the PPAR-{gamma} gene promoter. CCAAT/enhancer-binding protein induces expression of inflammatory cytokines but is inhibited by PPAR-{gamma} in the vasculature by transactivation (58).

PPAR-{gamma} activators (rosiglitazone and pioglitazone) prevented the BP rise and the structural, functional, and molecular changes induced by ANG II in blood vessels, inhibiting cell growth and inflammation (18). ANG II-induced small resistance artery remodeling and endothelial dysfunction were prevented. Vascular DNA synthesis, expression of cell cycle proteins, ANG AT1 receptors, VCAM-1, and platelet and endothelial cell adhesion molecule, and NF-{kappa}B activity, all of which were increased by ANG II infusion, were blunted by pioglitazone or rosiglitazone.

In DOCA-salt hypertensive rats, a hypertensive model associated with enhanced expression of preproendothelin (preproET)-1, BP increase was prevented in part by the PPAR-{gamma} activator rosiglitazone but not by the PPAR-{alpha} activator fenofibrate (26). Both PPAR activators, however, abrogated the increase of prepro-ET-1 mRNA in mesenteric blood vessels of these hypertensive rats and prevented the hypertrophic remodeling typically found in DOCA-salt rats. Rosiglitazone, but not fenofibrate, prevented endothelial dysfunction, but both abrogated the enhanced production of reactive oxygen species that occurs in blood vessels in DOCA-salt hypertensive rats.

Spontaneously hypertensive rats (SHR) exhibit insulin resistance, which has been associated with a mutation of cd36, which encodes for a fatty acid translocase. Insulin resistance thus results in decreased fatty acid translocation (1). cd36 is a target of PPAR-{gamma}. It has been speculated that expression of PPARs could be decreased in blood vessels of SHR, which would exacerbate proliferation, migration, inflammation, and fibrosis, as found in this hypertensive model. Indeed, human mutations of PPAR-{gamma} have been associated with diabetes, insulin resistance, and hypertension, all of which are accompanied by vascular disease (4). However, rather than decreased expression of PPAR-{alpha} and PPAR-{gamma} in blood vessels and cultured VSMCs from SHR, their expression was increased (20). This may result from a feedback response to the decreased activity of the mutant cd36 of SHR.

Mechanisms whereby PPAR-{gamma} activation improves endothelial function were investigated by Calnek et al. (8), who demonstrated that PPAR-{gamma} ligands, 15d-PGJ2, or ciglitazone increased NO release by porcine and human aortic endothelial cells. PPAR-{gamma} activation did not increase eNOS expression. Overexpression of PPAR-{gamma} or treatment with 9-cis-retinoic acid also enhanced NO release. Neither 15d-PGJ2 nor ciglitazone altered eNOS mRNA. Thus PPAR-{gamma} ligands stimulated NO release from endothelial cells through a transcriptional mechanism unrelated to eNOS expression (8).

Many studies have pointed toward an inhibitory role of PPARs in atherogenesis (40). The effect of rosiglitazone treatment on mechanisms involved in the initial stages of atherogenesis was evaluated in rabbits fed a high-cholesterol diet (59). Treatment with rosiglitazone enhanced the downregulated PPAR-{gamma} expression, improved endothelium-dependent vasodilatation, suppressed gp91phox and iNOS expression, reduced superoxide and total NO production, and inhibited nitrotyrosine formation. The endothelial protective effects of PPAR-{gamma} activators may reduce leukocyte accumulation in the vascular wall, contributing to antiatherosclerotic effects.

Ishibashi et al. (29) studied effects of pioglitazone in rats treated with N{omega}-nitro-L-arginine methyl ester to inhibit eNOS. The PPAR-{gamma} activator pioglitazone did not affect BP, metabolic state, or serum NO levels but prevented N{omega}-nitro-L-arginine methyl ester-induced coronary inflammation and arteriosclerosis. Pioglitazone did not reduce local expression of monocyte chemoattractant protein-1 but attenuated the expression of the monocyte chemoattractant protein-1 receptor C-C chemokine receptor 2 in monocytes in the vascular wall and in the circulation. It prevented coronary arteriosclerosis, possibly by downregulation of C-C chemokine receptor 2, which could represent a novel anti-inflammatory mechanism of PPAR-{gamma} activation independent of insulin sensitization.

A mechanism for improved endothelial function recently reported is the ability of PPAR-{gamma} activators to modulate bone marrow-derived angiogenic progenitor cells (APCs) to promote endothelial lineage differentiation and early reendothelialization after vascular intervention. Rosiglitazone treatment attenuated neointima formation in mice after femoral angioplasty (65). Rosiglitazone caused a sixfold increase in colony formation by human endothelial progenitor cells, promoted the differentiation of APCs toward the endothelial lineage in mouse bone marrow in vivo and in human peripheral blood in vitro, and inhibited the differentiation toward the SMC lineage. Within the neointima, rosiglitazone stimulated APCs to differentiate into mature endothelial cells and caused early reendothelialization compared with controls. Thus PPAR-{gamma} activators are able to promote differentiation of APCs toward the endothelial lineage and attenuate restenosis. Elevated levels of C-reactive protein (CRP) have been recognized as a powerful predictor of cardiovascular disease. Verma et al. (64) demonstrated that human recombinant CRP, at pathophysiologically relevant concentrations that predict adverse cardiovascular outcomes, inhibits endothelial progenitor cell (EPC) differentiation, survival, and function. The effects of CRP on EPC number, expression of endothelial cell-specific markers Tie-2, endothelial cell-lectin, and vascular endothelial cadherin, increased EPC apoptosis, and impaired eNOS expression and EPC-induced angiogenesis were attenuated by treatment with rosiglitazone, which may represent a mechanism that explains, in part, PPAR-{gamma} activation-induced cardioprotective effects.

VSMC proliferation is involved in vascular injury, restenosis, and atherosclerosis. Antiproliferative effects of the PPAR-{gamma} agonists troglitazone, rosiglitazone, and pioglitazone were investigated in cells derived from the internal mammary and radial artery and saphenous veins, vessels employed for coronary artery bypass grafting (11). The three activators of PPAR-{gamma} inhibited cell proliferation, with troglitazone being the most potent and rosiglitazone similar in potency to pioglitazone. Potency was therefore dependent on the PPAR-{gamma} activator independently of the vascular source of the cells.

Markers of systemic inflammation (CRP and IL-6), considered "nontraditional" risk factors for cardiovascular disease, are enhanced in patients with Type 2 diabetes mellitus. MMP-9 may participate in atherosclerotic plaque rupture. In patients treated with rosiglitazone for 26 wk, reductions in CRP, MMP-9, and white blood cell count were significantly correlated with insulin resistance, as estimated by the homeostasis model (HOMA) index, indicating potentially beneficial effects on cardiovascular risk in this patient population (25). Another emerging nontraditional risk factor implicated in atherosclerosis is the proinflammatory cytokine CD40 ligand (CD40L). Diabetic patients were shown to have elevated plasma levels of soluble CD40L (sCD40L) independent of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, BP, body mass index, gender, CRP, and soluble ICAM-1 (63). Treatment with troglitazone for 12 wk lowered sCD40L plasma levels in Type 2 diabetic patients, suggesting a novel anti-inflammatory mechanism for limiting diabetes-associated arterial disease. Other investigators showed similar results in patients with Type 2 diabetes and coronary artery disease (CAD). Thirty-nine patients with diabetes and angiographically proven CAD were treated with rosiglitazone for 12 wk (41). Rosiglitazone, but not placebo, significantly reduced sCD40L serum levels. This further underscores the ability of PPAR-{gamma}-activating thiazolidinediones to reduce sCD40L serum levels and exert anti-inflammatory and antiatherogenic effects.

Rosiglitazone has also been shown to reduce endothelial markers such as E-selectin and von Willebrand factor in nondiabetic CAD patients (54). Eighty-four patients with stable, angiographically documented CAD without diabetes mellitus were treated with rosiglitazone for 12 wk. Rosiglitazone significantly reduced E-selectin, von Willebrand factor, CRP, fibrinogen, and insulin resistance, as measured by HOMA index, compared with placebo. Thus PPAR-{gamma} activation reduced markers of endothelial cell activation and levels of acute-phase reactants in CAD patients without diabetes. In addition, other studies showed that these agents improve endothelial function of patients with the metabolic syndrome. Wang et al. (67) studied 50 nondiabetic patients who met a definition for the metabolic syndrome and were treated with rosiglitazone for 8 wk. These patients experienced significant reductions in fasting plasma insulin levels, HOMA index, BP, and high-sensitivity CRP. Rosiglitazone treatment significantly improved endothelium-dependent flow-mediated and endothelium-independent nitroglycerin-induced vasodilatation of the brachial artery. Carotid intima-media thickness has been considered a surrogate of endothelial function. In 92 nondiabetic patients with angiographically documented CAD studied by Sidhu et al. (55), the reduction in intima-media thickness progression after 48 wk of rosiglitazone treatment compared with the placebo group was associated with reduced insulin resistance (estimated by HOMA index). Thus PPAR activation improves endothelial dysfunction, which is thought to be a mechanism for initiation and progression of atherosclerosis, a risk factor and a participant in the triggering of cardiovascular events.

In a study of 136 Japanese Type 2 diabetic patients, pioglitazone was administered for 3 mo, and changes in glycolipid metabolism, plasma high-sensitivity CRP, leptin, adiponectin, and pulse wave velocity (PWV, a parameter that increases with the stiffness of blood vessels and is indicative of the presence of vascular injury) were evaluated to investigate the relation between the antiatherogenic and antidiabetic effects of pioglitazone (51). Pioglitazone treatment improved glucose metabolism, increased plasma adiponectin concentrations, and decreased CRP and PWV. Treatment with pioglitazone was associated with a low CRP and PWV independent of changes in carbohydrate metabolism. Thus the PPAR-{gamma} agonist exerted antiatherogenic effects independent of its antidiabetic action by lowering CRP, which contributes to vascular injury and the stiffness of blood vessels (a measure of vascular disease) and contributes to enhanced pulse pressure (another risk factor for vascular events).


   CARDIAC EFFECTS OF PPARS
TOP
 ABSTRACT
 VASCULAR EFFECTS OF PPAR-{alpha}
 VASCULAR EFFECTS OF PPAR-{gamma}
 CARDIAC EFFECTS OF PPARs
CONCLUSION
 GRANTS
 REFERENCES
 
PPAR-{alpha} regulates cardiac energy and lipid metabolism and plays a role in mitochondrial fatty acid {beta}-oxidation, which is critical for fuel generation in the heart (7). It serves as a molecular "lipostat" through the induction of target genes involved in fatty acid metabolism (22). PPAR-{alpha} controls myocardial lipid metabolism through activation of transcription of carnitine palmitoyltransferase I (7). In PPAR-{alpha}-null mice, the capacity for constitutive myocardial {beta}-oxidation of medium- and long-chain fatty acids was markedly reduced (68). Constitutive {beta}-oxidation of very-long-chain fatty acids such as lignoceric acid was unaffected in PPAR-{alpha}-deficient mice. This suggests that PPAR-{alpha} is not involved in the constitutive expression of enzymes that mediate {beta}-oxidation.

During cardiac hypertrophy, PPAR-{alpha} is inhibited (3), which reduces the capacity of hypertrophied myocytes to metabolize myocardial lipids, resulting in intracellular fat accumulation. PPAR-{alpha} activators inhibited cardiac expression of TNF-{alpha} and NF-{kappa}B induced by LPS (57). Fenofibrate reduced prepro-ET-1 mRNA expression and collagen type I and type III mRNA, associated with decreased interstitial and perivascular cardiac fibrosis after pressure overload induced by abdominal aortic banding (44), probably through suppression of AP-1-mediated prepro-ET-1 gene activation. Additionally, fenofibrate reduced cardiac hypertrophy and inflammation, associated with an increase in the anti-inflammatory cytokine IL-10 (39). Fenofibrate had beneficial effects on inflammation and collagen deposition in the heart of ANG II-infused rats (17). NF-{kappa}B activity and VCAM-1, platelet and endothelial cell adhesion molecule, ICAM-1, and ED-1 (macrophage antigen) expression were decreased, AT1 receptors were downregulated, and AT2 receptors were upregulated, which may be considered a beneficial change, because AT1 receptors are prohypertrophic, proinflammatory, and profibrotic, whereas AT2 receptors are generally shown to exert opposite effects.

The role of PPAR-{gamma} in the heart is less clear than that of PPAR-{alpha}. Expression of PPAR-{gamma} in the heart is very low (33). PPAR-{gamma} activators inhibited hypertrophy and brain natriuretic peptide expression in cultured cardiomyocytes (70). Aortic banding induced enhanced cardiac hypertrophy in heterozygous PPAR-{gamma}-deficient mice (2), suggesting an inhibitory effect of PPAR-{gamma} on cardiac growth. Pioglitazone, however, blunted myocardial hypertrophy in wild-type and PPAR-{gamma}–/– mice, suggesting an effect independent of activation of PPAR-{gamma}. ANG II-induced gene expression and cardiomyocyte hypertrophy were attenuated in vitro by thiazolidinediones. These data suggest that PPAR-{gamma} inhibits cardiac hypertrophy. In diabetic rats, PPAR-{gamma} improved left ventricular diastolic function and decreased collagen accumulation (61, 72) and also protected the myocardium from ischemic injury (53, 71). On the other hand, PPAR-{gamma} activators may trigger an aggravation of congestive heart failure (66, 69), which is counterintuitive with respect to the cardiovascular preventive potential of these drugs. This appears to be mainly due to fluid retention as a consequence of their insulinomimetic action on the kidney rather than a negative inotropic effect. Thus caution has been urged in the use of thiazolidinediones in diabetic patients with advanced heart failure (43), even though these agents may have cardiovascular protective properties in patients with less advanced cardiovascular disease.

The hypertrophic heart typically experiences an increase in glucose utilization and decreased fatty acid oxidation. It is unclear whether PPAR-{gamma} has effects on fatty acid metabolism comparable to those of PPAR-{alpha}. PPAR-{alpha} and PPAR-{gamma} have partially overlapping ligand binding profiles. Thus PPAR-{gamma} may mediate some intracellular signaling in cardiomyocytes similarly to PPAR-{alpha}, which could attenuate cardiac remodeling via signaling pathways not involved in the control of lipid and energy metabolism. Inflammation plays a critical role in the progression of cardiac remodeling and dysfunction. In macrophages, PPAR-{gamma} participates in the regulation of inflammatory responses by inhibition of transcription factors NF-{kappa}B and AP-1 (50). NF-{kappa}B is required for the hypertrophic response of neonatal rat cardiomyocytes in vitro (47). Recently, the PPAR-{gamma} activator pioglitazone was shown to have beneficial long-term effects on cardiac hypertrophy and cardiac inflammation but no effect on cardiac function in stroke-prone SHR (15). However, whether PPAR-{gamma} effects on the heart are exerted directly on cardiomyocytes or via infiltrating macrophages and other blood-borne cells or result from hormonal effects mediated from other organs has not been demonstrated (33).


   CONCLUSION
TOP
 ABSTRACT
 VASCULAR EFFECTS OF PPAR-{alpha}
 VASCULAR EFFECTS OF PPAR-{gamma}
 CARDIAC EFFECTS OF PPARs
 CONCLUSION
GRANTS
 REFERENCES
 
PPAR-{alpha} and PPAR-{gamma} modulate inflammatory, fibrotic, and hypertrophic responses in the cardiovascular system. The signaling pathways mediating the anti-inflammatory effect of PPARs, particularly in the heart, remain to be demonstrated. The contrast between the beneficial effect of PPAR-{gamma} activators on the heart in experimental models and clinical reports of decompensated heart failure in some diabetic patients treated with PPAR-{gamma} activators requires clarification. It is possible that salt and water retention induced by the insulin-sensitizing action of PPAR-{gamma} activators unmasks latent left ventricular dysfunction and precipitates heart failure not directly induced by actions of PPAR-{gamma} activators on the heart (66). Selective PPAR-{alpha} or PPAR-{gamma} activators, partial agonists or dual {alpha}/{gamma}-activators, may become interesting cardiovascular protective therapies in hypertension or other forms of cardiovascular disease in the near future.


   GRANTS
TOP
 ABSTRACT
 VASCULAR EFFECTS OF PPAR-{alpha}
 VASCULAR EFFECTS OF PPAR-{gamma}
 CARDIAC EFFECTS OF PPARs
 CONCLUSION
 GRANTS
REFERENCES
 
Work from the author's laboratory has been supported by Canadian Institutes of Health Research Grants 13570 and 37917 and a group grant to the Multidisciplinary Research Group on Hypertension.


   FOOTNOTES
 

Address for reprint requests and other correspondence: E. L. Schiffrin, Clinical Research Institute of Montreal, 110 Pine Ave. W, Montreal, Quebec, Canada H2W 1R7 (E-mail: ernesto.schiffrin{at}ircm.qc.ca)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 VASCULAR EFFECTS OF PPAR-{alpha}
 VASCULAR EFFECTS OF PPAR-{gamma}
 CARDIAC EFFECTS OF PPARs
 CONCLUSION
 GRANTS
 REFERENCES
 

  1. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, and Scott J. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 21: 76–83, 1999.[CrossRef][Web of Science][Medline]
  2. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T, and Komuro IF. Peroxisome proliferator-activated receptor {gamma} plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105: 1240–1246, 2002.[Abstract/Free Full Text]
  3. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, and Kelly DP. Deactivation of peroxisome proliferator-activated receptor-{alpha} during cardiac hypertrophic growth. J Clin Invest 105: 1723–1730, 2000.[Web of Science][Medline]
  4. Barroso I, Gurnell M, Crowley VEF, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TDM, Lewis H, Schafer AJ, Chatterjee VKK, and O'Rahilly S. Dominant negative mutations in human PPAR-{gamma} associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402: 880–883, 1999.[Medline]
  5. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 129: 823–834, 2000.[CrossRef][Web of Science][Medline]
  6. Braissant O, Foufelle F, Scotto C, Dauca M, and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-{alpha}, -{beta}, and -{gamma} in the adult rat. Endocrinology 137: 354–366, 1996.[Abstract]
  7. Brandt JM, Djouadi F, and Kelly DP. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor {alpha}. J Biol Chem 273: 23786–23792, 1998.[Abstract/Free Full Text]
  8. Calnek DS, Mazzella L, Roser S, Roman J, and Hart CM. Peroxisome proliferator-activated receptor-{gamma} ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 23: 52–57, 2003.[Abstract/Free Full Text]
  9. Chawla A, Lee CH, Barak Y, He W, Rosenfeld J, Liao D, Han J, Kang H, and Evans RM. PPAR{delta} is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci USA 100: 1268–1273, 2003.[Abstract/Free Full Text]
  10. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, and Staels B. Activation of proliferator-activated receptors {alpha} and {gamma} induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273: 25573–25580, 1998.[Abstract/Free Full Text]
  11. De Dios ST, Bruemmer D, Dilley RJ, Ivey ME, Jennings GLR, Law RE, and Little PJ. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-{gamma} ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 107: 2548–2550, 2003.[Abstract/Free Full Text]
  12. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, and Staels B. Peroxisome proliferator-activated receptor {alpha} negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-{kappa}B and AP-1. J Biol Chem 274: 32048–32054, 1999.[Abstract/Free Full Text]
  13. Delerive P, Fruchart C, and Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169: 453–459, 2001.[Abstract]
  14. Desvergne B and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649–688, 1999.[Abstract/Free Full Text]
  15. Diep QN, Amiri F, Benkirane K, Paradis P, and Schiffrin EL. Long-term effects of PPAR{gamma} activator pioglitazone on cardiac hypertrophy and inflammation in SHRSP. Can J Physiol Pharmacol. In press.
  16. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, and Schiffrin EL. PPAR{alpha} activator effects on ANG II-induced vascular oxidative stress and inflammation. Hypertension 40: 866–871, 2002.[Abstract/Free Full Text]
  17. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, and Schiffrin EL. PPAR{alpha} activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 36: 295–304, 2004.[CrossRef][Web of Science][Medline]
  18. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, and Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-{gamma}. Circulation 105: 2296–2302, 2002.[Abstract/Free Full Text]
  19. Diep QN, Intengan HD, and Schiffrin EL. Endothelin-1 attenuates {omega}-3 fatty acid-induced apoptosis by inhibition of caspase 3. Hypertension 35: 287–291, 2000.[Abstract/Free Full Text]
  20. Diep QN and Schiffrin EL. Increased expression of peroxisome proliferator-activated receptor-{alpha} and -{gamma} in blood vessels of spontaneously hypertensive rats. Hypertension 38: 249–254, 2001.[Abstract/Free Full Text]
  21. Diep QN, Touyz RM, and Schiffrin EL. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-{alpha} activator, induces apoptosis in vascular smooth muscle cells by activation of p38 mitogen-activated protein kinase. Hypertension 36: 851–855, 2000.[Abstract/Free Full Text]
  22. Djouadi F, Brandt JM, Weinheimer CJ, Leone TC, Gonzalez FJ, and Kelly DP. The role of the peroxisome proliferator-activated receptor {alpha} (PPAR {alpha}) in the control of cardiac lipid metabolism. Prostaglandins Leukot Essent Fatty Acids 60: 339–343, 1999.[CrossRef][Web of Science][Medline]
  23. Gilde AJ, van der Lee KAJM, Willemsen PHM, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, and van Bilsen M. Peroxisome proliferator-activated receptor (PPAR) {alpha} and PPAR{beta}/{delta}, but not PPAR{gamma}, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92: 518–524, 2003.[Abstract/Free Full Text]
  24. Goya K, Sumitani S, Xu X, Kitamura T, Yamamoto H, Kurebayashi S, Saito H, Kouhara H, Kasayama S, and Kawase I. Peroxisome proliferator-activated receptor {gamma} agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 24: 658–663, 2004.[Abstract/Free Full Text]
  25. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, and Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106: 679–684, 2002.[Abstract/Free Full Text]
  26. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, and Schiffrin EL. Effect of peroxisome proliferator-activated receptor-{alpha} and -{gamma} activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 23: 45–51, 2003.[Abstract/Free Full Text]
  27. Ijpenberg A, Jeannin E, Wahli W, and Desvergne B. Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J Biol Chem 272: 20108–20117, 1997.[Abstract/Free Full Text]
  28. Inoue I, Shino K, Noji S, Awata T, and Katayama S. Expression of peroxisome proliferator-activated receptor {alpha} (PPAR{alpha}) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 246: 370–374, 1998.[CrossRef][Web of Science][Medline]
  29. Ishibashi M, Egashira K, Hiasa Ki Inoue S, Ni W, Zhao Q, Usui M, Kitamoto S, Ichiki T, and Takeshita A. Anti-inflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 40: 687–693, 2002.[Abstract/Free Full Text]
  30. Issemann I and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645–650, 1990.[CrossRef][Medline]
  31. Jiang C, Ting AT, and Seed B. PPAR-{gamma} agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82–86, 1998.[CrossRef][Medline]
  32. Jozkowicz A, Dulak J, Prager M, Nanobashvili J, Nigisch A, Winter B, Weigel G, and Huk I. Prostaglandin-J2 induces synthesis of interleukin-8 by endothelial cells in a PPAR-{gamma}-independent manner. Prostaglandins Other Lipid Mediat 66: 165–177, 2001.[CrossRef][Web of Science][Medline]
  33. Kelly DP. PPARs of the heart. Circ Res 92: 482–484, 2003.[Free Full Text]
  34. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, and Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91: 7355–7359, 1994.[Abstract/Free Full Text]
  35. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, and Hsueh WA. Expression and function of PPAR{gamma} in rat and human vascular smooth muscle cells. Circulation 101: 1311–1318, 2000.[Abstract/Free Full Text]
  36. Law RE and Hsueh WA. PPAR{gamma} and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 21: 1891–1895, 2001.[Abstract/Free Full Text]
  37. Llopis J, Westin S, Ricote M, Wang Z, Cho CY, Kurokawa R, Mullen TM, Rose DW, Rosenfeld MG, Tsien RY, Glass CK, and Wang J. Ligand-dependent interactions of coactivators steroid receptor coactivator-1 and peroxisome proliferator-activated receptor binding protein with nuclear hormone receptors can be imaged in live cells and are required for transcription. Proc Natl Acad Sci USA 97: 4363–4368, 2000.[Abstract/Free Full Text]
  38. Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B, Kalina Z, and Herman ZS. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther 36: 345–349, 1998.[Web of Science][Medline]
  39. Maruyama S, Kato K, Kodama M, Hirono S, Fuse K, Nakagawa O, Nakazawa M, Miida T, Yamamoto T, Watanabe K, and Aizawa Y. Fenofibrate, a peroxisome proliferator-activated receptor-{alpha} activator, suppresses experimental autoimmune myocarditis by stimulating the interleukin-10 pathway in rats. J Atheroscler Thromb 9: 87–92, 2002.[Medline]
  40. Marx N, Duez H, Fruchart JC, and Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94: 1168–1178, 2004.[Abstract/Free Full Text]
  41. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Hombach V, and Koenig W. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 107: 1954–1957, 2003.[Abstract/Free Full Text]
  42. Marx N, Sukhova GK, Collins T, Libby P, and Plutzky J. PPAR{alpha} activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99: 3125–3131, 1999.[Abstract/Free Full Text]
  43. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, and Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108: 2941–2948, 2003.[Free Full Text]
  44. Ogata T, Miyauchi T, Sakai S, Irukayama-Tomobe Y, Goto K, and Yamaguchi I. Stimulation of peroxisome-proliferator-activated receptor {alpha} (PPAR{alpha}) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci (Lond) 103, Suppl 1:284S–288S, 2002.
  45. Pasceri V, Wu HD, Willerson JT, and Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-{gamma} activators. Circulation 101: 235–238, 2000.[Abstract/Free Full Text]
  46. Poynter ME and Daynes RA. Peroxisome proliferator-activated receptor {alpha} activation modulates cellular redox status, represses nuclear factor-{kappa}B signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273: 32833–32841, 1998.[Abstract/Free Full Text]
  47. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, and Lin A. Activation of NF-{kappa}B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci USA 98: 6668–6673, 2001.[Abstract/Free Full Text]
  48. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, and Glass CK. Expression of the peroxisome proliferator-activated receptor{gamma} (PPAR{gamma}) in human atherosclerosis and regulation in macrophages by colony-stimulating factors and oxidized low-density lipoprotein. Proc Natl Acad Sci USA 95: 7614–7619, 1998.[Abstract/Free Full Text]
  49. Ricote M, Huang JT, Welch JS, and Glass CK. The peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) as a regulator of monocyte/macrophage function. J Leukoc Biol 66: 733–739, 1999.[Abstract]
  50. Ricote M, Li AC, Willson TM, Kelly CJ, and Glass CK. The peroxisome proliferator-activated receptor-{gamma} is a negative regulator of macrophage activation. Nature 391: 79–82, 1998.[CrossRef][Medline]
  51. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, and Nakao K. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26: 2493–2499, 2003.[Abstract/Free Full Text]
  52. Satoh H, Tsukamoto K, Hashimoto Y, Hashimoto N, Togo M, Hara M, Maekawa H, Isoo N, Kimura S, and Watanabe T. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPAR{gamma} on vascular endothelial function. Biochem Biophys Res Commun 254: 757–763, 1999.[CrossRef][Web of Science][Medline]
  53. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, and Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes 51: 1110–1117, 2002.[Abstract/Free Full Text]
  54. Sidhu JS, Cowan D, and Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-{gamma} agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 42: 1757–1763, 2003.[Abstract/Free Full Text]
  55. Sidhu JS, Kaposzta Z, Markus HS, and Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24: 930–934, 2004.[Abstract/Free Full Text]
  56. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, and Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPAR{alpha} but not by PPAR{gamma} activators. Nature 393: 790–793, 1998.[CrossRef][Medline]
  57. Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I, Saito T, and Masuda Y. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-{alpha} expression in neonatal rat cardiac myocytes. Circ Res 87: 596–602, 2000.[Abstract/Free Full Text]
  58. Takata Y, Kitami Y, Yang ZH, Nakamura M, Okura T, and Hiwada K. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-{delta} and peroxisome proliferator-activated receptor-{gamma}. Circ Res 91: 427–433, 2002.[Abstract/Free Full Text]
  59. Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, Ma XL, Batinic-Haberle I, Willette RN, Ohlstein EH, and Yue TL. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-{gamma} agonist in hypercholesterolemia. Circulation 108: 2805–2811, 2003.[Abstract/Free Full Text]
  60. Tontonoz P, Hu E, and Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR{gamma}2, a lipid-activated transcription factor. Cell 79: 1147–1156, 1994.[CrossRef][Web of Science][Medline]
  61. Tsuji T, Mizushige K, Noma T, Murakami K, Ohmori K, Miyatake A, and Kohno M. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol 38: 868–874, 2001.[CrossRef][Web of Science][Medline]
  62. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, and Green S. The mouse peroxisome proliferator-activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J 11: 433–439, 1992.[Web of Science][Medline]
  63. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, Fernandez-Cruz A, Veves A, Jarolim P, Varo JJ, Goldfine A, Horton E, and Schonbeck U. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 107: 2664–2669, 2003.[Abstract/Free Full Text]
  64. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, Badiwala MV, Mickle DAG, Weisel RD, Fedak PWM, Stewart DJ, and Kutryk MJB. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109: 2058–2067, 2004.[Abstract/Free Full Text]
  65. Wang CH, Ciliberti N, Li SH, Szmitko PE, Weisel RD, Fedak PWM, Al Omran M, Cherng WJ, Li RK, Stanford WL, and Verma S. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 109: 1392–1400, 2004.[Abstract/Free Full Text]
  66. Wang CH, Weisel RD, Liu PP, Fedak PWM, and Verma S. Glitazones and heart failure: critical appraisal for the clinician. Circulation 107: 1350–1354, 2003.[Free Full Text]
  67. Wang TD, Chen WJ, Lin JW, Chen MF, and Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 93: 362–365, 2004.[CrossRef][Web of Science][Medline]
  68. Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y, Ono T, Hasegawa G, Naito M, Nakajima T, Kamijo Y, Gonzalez FJ, and Aoyama T. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor {alpha} associated with age-dependent cardiac toxicity. J Biol Chem 275: 22293–22299, 2000.[Abstract/Free Full Text]
  69. Wooltorton E. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. Can Med Assoc J 166: 219, 2002.[Free Full Text]
  70. Yamamoto K, Ohki R, Lee RT, Ikeda U, and Shimada K. Peroxisome proliferator-activated receptor {gamma} activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104: 1670–1675, 2001.[Abstract/Free Full Text]
  71. Yue TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, and Ohlstein EH. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-{gamma} agonist rosiglitazone. Circulation 104: 2588–2594, 2001.[Abstract/Free Full Text]
  72. Zhu P, Lu L, Xu Y, and Schwartz GG. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 101: 1165–1171, 2000.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Circ. Res.Home page
E. L. Schiffrin and P. Paradis
Suppression of Peroxisome Proliferator-Activated Receptor-{gamma} Activity by Angiotensin II in Vascular Smooth Muscle Involves Bcr Kinase: The Fire That Drowns The Water
Circ. Res., January 2, 2009; 104(1): 4 - 6.
[Full Text] [PDF]

Home page
 Cardiovasc ResHome page
Q. Zhang, F. He, R. Kuruba, X. Gao, A. Wilson, J. Li, T. R. Billiar, B. R. Pitt, W. Xie, and S. Li
FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells
Cardiovasc Res, February 1, 2008; 77(3): 560 - 569.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. E. Buroker, M. E. Young, C. Wei, K. Serikawa, M. Ge, X.-H. Ning, and M. A. Portman
The dominant negative thyroid hormone receptor beta-mutant {Delta}337T alters PPAR{alpha} signaling in heart
Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E453 - E460.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
V. Subramanian, P. Krishnamurthy, K. Singh, and M. Singh
Lack of osteopontin improves cardiac function in streptozotocin-induced diabetic mice
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H673 - H683.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
P. Rocic, B. Rezk, and P. A. Lucchesi
PPAR-{gamma} agonists decrease hyperhomcysteinemia and cardiac dysfunction: new hope for ailing diabetic hearts?
Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H26 - H28.
[Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
S. Mitchell, A. Ota, W. Foster, B. Zhang, Z. Fang, S. Patel, S. F. Nelson, S. Horvath, and Y. Wang
Distinct gene expression profiles in adult mouse heart following targeted MAP kinase activation
Physiol Genomics, March 13, 2006; 25(1): 50 - 59.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
R. Agarwal
Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy
Am J Physiol Renal Physiol, March 1, 2006; 290(3): F600 - F605.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/3/H1037    most recent
00677.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (31)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schiffrin, E. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schiffrin, E. L.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.